PTC THERAPEUTICS INC (PTCT) Stock Fundamental Analysis
NASDAQ:PTCT - Nasdaq - US69366J2006 - Common Stock - Currency: USD
PTCT gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. PTCT has only an average score on both its financial health and profitability. PTCT is growing strongly while it is still valued neutral. This is a good combination! These ratings could make PTCT a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
PTCT had positive earnings in the past year.
In the past year PTCT had a positive cash flow from operations.
In the past 5 years PTCT always reported negative net income.
PTCT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 22.40%, PTCT belongs to the top of the industry, outperforming 98.21% of the companies in the same industry.
PTCT has a Return On Invested Capital of 33.50%. This is amongst the best in the industry. PTCT outperforms 99.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.4% | ||
| ROE | N/A | ||
| ROIC | 33.5% |
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 33.55%, PTCT belongs to the best of the industry, outperforming 97.32% of the companies in the same industry.
PTCT has a better Operating Margin (49.27%) than 99.82% of its industry peers.
Looking at the Gross Margin, with a value of 96.87%, PTCT belongs to the top of the industry, outperforming 96.96% of the companies in the same industry.
PTCT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 49.27% | ||
| PM (TTM) | 33.55% | ||
| GM | 96.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PTCT is creating value.
PTCT has more shares outstanding than it did 1 year ago.
PTCT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PTCT has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 1.92 indicates that PTCT is not a great score, but indicates only limited risk for bankruptcy at the moment.
PTCT's Altman-Z score of 1.92 is fine compared to the rest of the industry. PTCT outperforms 70.66% of its industry peers.
PTCT has a debt to FCF ratio of 3.47. This is a good value and a sign of high solvency as PTCT would need 3.47 years to pay back of all of its debts.
The Debt to FCF ratio of PTCT (3.47) is better than 93.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.47 | ||
| Altman-Z | 1.92 |
ROIC/WACC3.23
WACC10.37%
2.3 Liquidity
PTCT has a Current Ratio of 3.89. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.89, PTCT is in line with its industry, outperforming 44.36% of the companies in the same industry.
A Quick Ratio of 3.85 indicates that PTCT has no problem at all paying its short term obligations.
PTCT has a Quick ratio (3.85) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.89 | ||
| Quick Ratio | 3.85 |
3. Growth
3.1 Past
PTCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 189.25%, which is quite impressive.
The Revenue has grown by 91.12% in the past year. This is a very strong growth!
Measured over the past years, PTCT shows a very strong growth in Revenue. The Revenue has been growing by 21.32% on average per year.
EPS 1Y (TTM)189.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%936.67%
Revenue 1Y (TTM)91.12%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%459.73%
3.2 Future
The Earnings Per Share is expected to grow by 21.66% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 11.69% on average over the next years. This is quite good.
EPS Next Y181.26%
EPS Next 2Y22.09%
EPS Next 3Y23.98%
EPS Next 5Y21.66%
Revenue Next Year115.86%
Revenue Next 2Y2.54%
Revenue Next 3Y9.67%
Revenue Next 5Y11.69%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 9.80, the valuation of PTCT can be described as very reasonable.
PTCT's Price/Earnings ratio is rather cheap when compared to the industry. PTCT is cheaper than 97.32% of the companies in the same industry.
When comparing the Price/Earnings ratio of PTCT to the average of the S&P500 Index (26.32), we can say PTCT is valued rather cheaply.
PTCT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.8 | ||
| Fwd PE | N/A |
4.2 Price Multiples
99.11% of the companies in the same industry are more expensive than PTCT, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, PTCT is valued cheaply inside the industry as 98.57% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.86 | ||
| EV/EBITDA | 4.32 |
4.3 Compensation for Growth
PTCT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PTCT's earnings are expected to grow with 23.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y22.09%
EPS Next 3Y23.98%
5. Dividend
5.1 Amount
PTCT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
51.26
+0.28 (+0.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners100.78%
Inst Owner Change2.67%
Ins Owners0.63%
Ins Owner Change3.97%
Market Cap4.06B
Analysts78.18
Price Target62.37 (21.67%)
Short Float %6.68%
Short Ratio3.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2260.84%
Min EPS beat(2)-221.32%
Max EPS beat(2)4742.99%
EPS beat(4)2
Avg EPS beat(4)1127.12%
Min EPS beat(4)-221.32%
Max EPS beat(4)4742.99%
EPS beat(8)3
Avg EPS beat(8)526.16%
EPS beat(12)3
Avg EPS beat(12)339.46%
EPS beat(16)4
Avg EPS beat(16)251.33%
Revenue beat(2)1
Avg Revenue beat(2)287.62%
Min Revenue beat(2)-10.09%
Max Revenue beat(2)585.33%
Revenue beat(4)2
Avg Revenue beat(4)146.44%
Min Revenue beat(4)-10.09%
Max Revenue beat(4)585.33%
Revenue beat(8)4
Avg Revenue beat(8)74.22%
Revenue beat(12)7
Avg Revenue beat(12)50.19%
Revenue beat(16)10
Avg Revenue beat(16)39.08%
PT rev (1m)-2.17%
PT rev (3m)-1.75%
EPS NQ rev (1m)0.85%
EPS NQ rev (3m)18.64%
EPS NY rev (1m)0%
EPS NY rev (3m)788.16%
Revenue NQ rev (1m)-0.5%
Revenue NQ rev (3m)3.56%
Revenue NY rev (1m)11.27%
Revenue NY rev (3m)107.91%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.8 | ||
| Fwd PE | N/A | ||
| P/S | 2.29 | ||
| P/FCF | 5.86 | ||
| P/OCF | 5.87 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.32 |
EPS(TTM)5.23
EY10.2%
EPS(NY)-3.06
Fwd EYN/A
FCF(TTM)8.74
FCFY17.06%
OCF(TTM)8.73
OCFY17.02%
SpS22.37
BVpS-2.34
TBVpS-4.88
PEG (NY)0.05
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.4% | ||
| ROE | N/A | ||
| ROCE | 42.4% | ||
| ROIC | 33.5% | ||
| ROICexc | 2102.85% | ||
| ROICexgc | N/A | ||
| OM | 49.27% | ||
| PM (TTM) | 33.55% | ||
| GM | 96.87% | ||
| FCFM | 39.09% |
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
F-Score8
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.47 | ||
| Debt/EBITDA | 2.39 | ||
| Cap/Depr | 4.95% | ||
| Cap/Sales | 0.08% | ||
| Interest Coverage | 202.52 | ||
| Cash Conversion | 76.77% | ||
| Profit Quality | 116.5% | ||
| Current Ratio | 3.89 | ||
| Quick Ratio | 3.85 | ||
| Altman-Z | 1.92 |
F-Score8
WACC10.37%
ROIC/WACC3.23
Cap/Depr(3y)15.16%
Cap/Depr(5y)26.1%
Cap/Sales(3y)2.81%
Cap/Sales(5y)3.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)189.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%936.67%
EPS Next Y181.26%
EPS Next 2Y22.09%
EPS Next 3Y23.98%
EPS Next 5Y21.66%
Revenue 1Y (TTM)91.12%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%459.73%
Revenue Next Year115.86%
Revenue Next 2Y2.54%
Revenue Next 3Y9.67%
Revenue Next 5Y11.69%
EBIT growth 1Y684.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year750.07%
EBIT Next 3Y65.9%
EBIT Next 5YN/A
FCF growth 1Y315.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y339.54%
OCF growth 3YN/A
OCF growth 5YN/A